Royalty Pharma (FRA:RPD) Inventory Turnover: 0.00 (As of Mar. 2026)

What is Royalty Pharma Inventory Turnover?

Royalty Pharma FRA:RPD -1.91% 67 Inventory Turnover is 0.00 as of Mar. 2026. GuruFocus rates FRA:RPD with a GF Score™ of 67/100 and a GF Value™ of €32.32 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Royalty Pharma's Cost of Goods Sold for the three months ended in Mar. 2026 was €0 Mil. Royalty Pharma's Average Total Inventories for the quarter that ended in Mar. 2026 was €0 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Royalty Pharma's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.00.

Royalty Pharma (FRA:RPD) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Royalty Pharma's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2026 )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Royalty Pharma's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	0	/	545.448
	=	0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Royalty Pharma Inventory Turnover Related Terms

Royalty Pharma Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Royalty Pharma's Inventory Turnover can be seen below:

Royalty Pharma Inventory Turnover Chart

Royalty Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Inventory Turnover

Get a 7-Day Free Trial

0.00

Royalty Pharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Inventory Turnover	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

67GF Score

Royalty Pharma PLC FRA:RPD

Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Royalty Pharma Inventory Turnover Calculation

Royalty Pharma's Inventory Turnover for the fiscal year that ended in Dec. 2025 is calculated as

	Inventory Turnover (A: Dec. 2025 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Dec. 2025 )	/ (	(Total Inventories (A: Dec. 2024 )	+	Total Inventories (A: Dec. 2025 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Royalty Pharma's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

	Inventory Turnover (Q: Mar. 2026 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Mar. 2026 )	/ (	(Total Inventories (Q: Dec. 2025 )	+	Total Inventories (Q: Mar. 2026 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Frequently Asked Questions Learn more about Inventory Turnover →

What does a Inventory Turnover of 0.00 mean?

Royalty Pharma (FRA:RPD) has a Inventory Turnover of 0.00 as of Mar. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Royalty Pharma and its competitors.

Is Royalty Pharma's Inventory Turnover too high?

Royalty Pharma's current Inventory Turnover is 0.00. Overall, Royalty Pharma has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Royalty Pharma's Inventory Turnover compare to ROIV and MRNA?

Royalty Pharma's Inventory Turnover of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Inventory Turnover for a Biotechnology company?

A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Inventory Turnover mean?

A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current Inventory Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Royalty Pharma stock overvalued right now?

Based on GuruFocus' analysis, Royalty Pharma (FRA:RPD) is currently considered Significantly Overvalued. The stock's GF Value™ is €32.32, compared to a current price of €47.73 — trading 47.7% above its estimated fair value. The current Inventory Turnover is 0.00. Royalty Pharma's overall GF Score™ is 67/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Inventory Turnover calculated?

Inventory Turnover is calculated from a company's financial statements. For Royalty Pharma (FRA:RPD), the current Inventory Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Royalty Pharma (FRA:RPD) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of €47.73 is trading 47.7% above its estimated GF Value™ of €32.32. GuruFocus considers Royalty Pharma to be Significantly Overvalued.

Key valuation signals for FRA:RPD:

Inventory Turnover: 0.00
GF Value™: €32.32 vs. price of €47.73 (47.7% above fair value)
GF Score™: 67/100 with 10 warning signs

No single metric tells the full story. See the FRA:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Industry Healthcare Biotechnology

Comparable Companies ROIV MRNA BNTX INCY INSM ONC ASND JAZZ BBIO EXEL VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD XKRX:068270 HKSE:02269

Other Exchanges RPRX:USA

Address 110 East 59th Street, New York, NY, USA, 10022

Website https://www.royaltypharma.com

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

67GF Score

Get the complete analysis for FRA:RPD

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€47.73

Price

€32.32

GF Value

View FRA:RPD Analysis

See Inventory Turnover data for all stocks →